THCA Therapeutics has expanded its scientific evidence review to include published and registered human research involving THCA. The identified evidence includes controlled oral administration, Phase I clinical investigation and systemic detection of THCA in humans.

These findings do not establish clinical efficacy of purified THCA or THCA PURE™ Oral in Rheumatoid Arthritis. They do, however, strengthen the translational starting point for the company’s development program by demonstrating that THCA has already entered human research.

The remaining question is the one THCA Therapeutics intends to address through pharmaceutical development: whether purified THCA can be developed as a reproducible therapeutic candidate, beginning with THCA PURE™ Oral in Rheumatoid Arthritis.